tetano
Editor, Senior Moderator
Vaccine. 2012 Oct 25. pii: S0264-410X(12)01494-6. doi: 10.1016/j.vaccine.2012.10.048. [Epub ahead of print]
Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania.
Fox CB, Huynh C, O'Hara MK, Onu A.
Source
Infectious Disease Research Institute, 1124 Columbia St., Ste 400, Seattle, WA 98104, United States. Electronic address: cfox@idri.org.
Abstract
Many developing countries lack or have inadequate pandemic influenza vaccine manufacturing capacity. In the 2009 H1N1 pandemic, this led to delayed and inadequate vaccine coverage in the developing world. Thus, bolstering developing country influenza vaccine manufacturing capacity is urgently needed. The Cantacuzino Institute in Bucharest, Romania has been producing seasonal influenza vaccine since the 1970s, and has the capacity to produce ∼5 million doses of monovalent vaccine in the event of an influenza pandemic. Inclusion of an adjuvant in the vaccine could enable antigen dose sparing, expanding vaccine coverage and potentially allowing universal vaccination of the Romanian population and possibly neighboring countries. However, adjuvant formulation and manufacturing know-how are difficult to access. This manuscript describes the successful transfer of oil-in-water emulsion adjuvant manufacturing and quality control technologies from the Infectious Disease Research Institute in Seattle, USA to the Cantacuzino Institute. By describing the challenges and accomplishments of the project, it is hoped that the knowledge and experience gained will benefit other institutes involved in similar technology transfer projects designed to facilitate increased vaccine manufacturing capacity in developing countries'.
Copyright ? 2012. Published by Elsevier Ltd.
PMID:
23103197
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23103197
Technology transfer of oil-in-water emulsion adjuvant manufacturing for pandemic influenza vaccine production in Romania.
Fox CB, Huynh C, O'Hara MK, Onu A.
Source
Infectious Disease Research Institute, 1124 Columbia St., Ste 400, Seattle, WA 98104, United States. Electronic address: cfox@idri.org.
Abstract
Many developing countries lack or have inadequate pandemic influenza vaccine manufacturing capacity. In the 2009 H1N1 pandemic, this led to delayed and inadequate vaccine coverage in the developing world. Thus, bolstering developing country influenza vaccine manufacturing capacity is urgently needed. The Cantacuzino Institute in Bucharest, Romania has been producing seasonal influenza vaccine since the 1970s, and has the capacity to produce ∼5 million doses of monovalent vaccine in the event of an influenza pandemic. Inclusion of an adjuvant in the vaccine could enable antigen dose sparing, expanding vaccine coverage and potentially allowing universal vaccination of the Romanian population and possibly neighboring countries. However, adjuvant formulation and manufacturing know-how are difficult to access. This manuscript describes the successful transfer of oil-in-water emulsion adjuvant manufacturing and quality control technologies from the Infectious Disease Research Institute in Seattle, USA to the Cantacuzino Institute. By describing the challenges and accomplishments of the project, it is hoped that the knowledge and experience gained will benefit other institutes involved in similar technology transfer projects designed to facilitate increased vaccine manufacturing capacity in developing countries'.
Copyright ? 2012. Published by Elsevier Ltd.
PMID:
23103197
[PubMed - as supplied by publisher]
http://www.ncbi.nlm.nih.gov/pubmed/23103197